Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25067391 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL197946 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL13366885 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL25863106 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL13366876 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL19390704 | 0.84 | MAPT (0.43) | ALDH1A1CNR1CNR2 | |
| SCHEMBL129632 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL131684 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CNR1CNR2TRPV1GBA1 | |
| SCHEMBL202180 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2 | |
| SCHEMBL202102 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20160317676-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-11-03 | — | — | US | disclosed |
| US-8722082-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-13 | — | — | US | disclosed |
| US-20130017223-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-17 | — | — | US | disclosed |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011075656-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010054384-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885 |
| US-20130017223-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, APOB, LIPC | ALDH1A1 4338/4885CNR1 3995/4885CNR2 3641/4885 |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ABCB4, CETP, SGMS1 | ALDH1A1 3777/4885CNR1 2763/4885CNR2 2760/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885 |
| US-20160317676-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, APOB, LIPC | ALDH1A1 4338/4885CNR1 3995/4885CNR2 3641/4885 |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885CNR1 4492/4885CNR2 4726/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885CNR1 4492/4885CNR2 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.